How Novo Nordisk and UNC Health are using N3C resources to accelerate research on COVID-19 and metabolic disease

In this podcast, Novo Nordisk researcher Dr. Kajsa Kvist and Dr. John Buse from the University of North Carolina at Chapel Hill discuss how and why Novo Nordisk became an early participant of the National COVID-19 Collaborative (N3C) as a tool to study the pandemic.

The Novo Nordisk patient analytics team led by Dr. Kvist is studying how COVID-19 affects patients with diabetes to learn how their products can help infected patients. The collaborators discuss the working model they established to leverage the strengths of academic and industry partners through the N3C.

"We are proud to participate in these ambitious endeavors to support clinicians and the patients living with serious chronic diseases. The high quality real world data available empowers us to obtain key insights in the treatment of type 2 diabetics in connection with COVID-19 substantially faster with the ultimate aim of supporting our patients worldwide."
Martin Lange, senior vice president for Global Development, Novo Nordisk

View the transcript at graticule.life.